文献速递胸部肿瘤

非小细胞肺癌中非整倍体与染色体9p缺失对肿瘤免疫微环境及免疫检查点抑制剂疗效的影响

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
PubMed 文献 · J Thorac Oncol · 2023-05-27

在两家学术中心接受PD-1或PD-L1抑制剂治疗的非鳞NSCLC中,非整倍体负荷(FAA)越低,ORR、mPFS和mOS越好;染色体9p缺失与更差的免疫治疗疗效独立相关。高FAA或9p缺失的肿瘤具有较少的肿瘤相关细胞毒性免疫细胞。

要点

  • FAA中位值随分期升高而增加,随PD-L1 TPS升高而降低(TPS<1%:0.09,TPS 1%-49%:0.08,TPS≥50%:0.05,p<0.0001)。
  • FAA三分位越低,ORR、mPFS和mOS逐步改善(ORR 15.1% vs 23.2% vs 28.4%,p=0.001)。
  • 染色体9p缺失者较无9p缺失者ORR更低(7.8% vs 28.1%)、mPFS更短(2.3 vs 4.1月)、mOS更短(9.6 vs 18.0月)。

核心结论

  • 高非整倍体负荷和染色体9p缺失的非鳞NSCLC具有独特的肿瘤免疫微环境,且对免疫检查点抑制剂疗效较差。

研究设计与样本

  • 在两家学术中心接受PD-1或PD-L1抑制剂治疗的非鳞NSCLC患者纳入研究,对接受靶向下一代测序的非鳞NSCLC回顾性量化非整倍体(FAA)。
  • 共识别2293例非鳞NSCLC,其中765例晚期非鳞NSCLC有FAA值并接受ICI治疗。

主要发现

  • FAA中位值随分期升高而增加,随PD-L1 TPS升高而降低(TPS<1%:0.09,TPS 1%-49%:0.08,TPS≥50%:0.05,p<0.0001)。
  • FAA与TMB连续变量相关性极弱(R=0.07,p=0.0005)。
  • FAA三分位从高到低,ORR分别为15.1%、23.2%、28.4%(p=0.001),mPFS分别为2.5、3.3、4.1个月(p<0.0001),mOS分别为12.5、13.9、16.4个月(p=0.006)。
  • 染色体9p缺失(OR=0.22,Q=0.0002)和1q获得(OR=0.43,Q=0.002)在ICI无应答者中显著富集。
  • 多变量分析中,校正FAA等关键变量后,9p缺失(而非1q获得)对ORR(HR=0.25,p<0.001)、mPFS(HR=1.49,p=0.001)和mOS(HR=1.47,p=0.003)仍有显著影响。

关键数值与推荐

  • 染色体臂改变定义为至少70%的臂区域发生获得或缺失。
  • FAA定义为改变的染色体臂数除以评估的染色体臂数,并按肿瘤纯度校正。
  • 9p缺失者(n=154)较无9p缺失者(n=452)ORR更低(7.8% vs 28.1%,p<0.0001),mPFS更短(2.3 vs 4.1月,p<0.0001),mOS更短(9.6 vs 18.0月,p<0.0001)。
  • 在PD-L1 TPS≥50%的NSCLC中,9p缺失者较无9p缺失者ORR更低(6% vs 43%,p<0.0001),mPFS更短(2.6 vs 6.4月,p=0.0006),mOS更短(14.3 vs 30.2月,p=0.0008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although gene-level copy number alterations have been studied as a potential biomarker of immunotherapy efficacy in NSCLC, the impact of aneuploidy burden and chromosomal arm-level events on immune checkpoint inhibitor (ICI) efficacy in NSCLC is uncertain. METHODS: Patients who received programmed cell death protein 1 or programmed death-ligand 1 (PD-L1) inhibitor at two academic centers were included. Across all 22 chromosomes analyzed, an arm was considered altered if at least 70% of its territory was either gained or deleted. Among nonsquamous NSCLCs which underwent targeted next-generation sequencing, we retrospectively quantified aneuploidy using the adjusted fraction of chromosomal arm alterations (FAA), defined as the number of altered chromosome arms divided by the number of chromosome arms assessed, adjusted for tumor purity. RESULTS: Among 2293 nonsquamous NSCLCs identified, the median FAA increased with more advanced cancer stage and decreased with higher PD-L1 tumor proportion score (TPS) levels (median FAA in TPS < 1%: 0.09, TPS 1%-49%: 0.08, TPS ≥ 50%: 0.05, p < 0.0001). There was a very weak correlation between FAA and tumor mutational burden when taken as continuous variables (R: 0.07, p = 0.0005). A total of 765 advanced nonsquamous NSCLCs with available FAA values were treated with ICIs. With decreasing FAA tertiles, there was a progressive improvement in objective response rate (ORR 15.1% in upper tertile versus 23.2% in middle tertile versus 28.4% in lowest tertile, p = 0.001), median progression-free survival (mPFS 2.5 versus 3.3 versus 4.1 mo, p < 0.0001), and median overall survival (mOS 12.5 versus 13.9 versus 16.4 mo, p = 0.006), respectively. In the arm-level enrichment analysis, chromosome 9p loss (OR = 0.22, Q = 0.0002) and chromosome 1q gain (OR = 0.43, Q = 0.002) were significantly enriched in ICI nonresponders after false discovery rate adjustment. Compared with NSCLCs without chromosome 9p loss (n = 452), those with 9p loss (n = 154) had a lower ORR (28.1% versus 7.8%, p < 0.0001), a shorter mPFS (4.1 versus 2.3 mo, p < 0.0001), and a shorter mOS (18.0 versus 9.6 mo, p < 0.0001) to immunotherapy. In addition, among NSCLCs with high PD-L1 expression (TPS ≥ 50%), chromosome 9p loss was associated with lower ORR (43% versus 6%, p < 0.0001), shorter mPFS (6.4 versus 2.6 mo, p = 0.0006), and shorter mOS (30.2 versus 14.3 mo, p = 0.0008) to immunotherapy compared with NSCLCs without 9p loss. In multivariable analysis, adjusting for key variables including FAA, chromosome 9p loss, but not 1q gain, retained a significant impact on ORR (hazard ratio [HR] = 0.25, p < 0.001), mPFS (HR = 1.49, p = 0.001), and mOS (HR = 1.47, p = 0.003). Multiplexed immunofluorescence and computational deconvolution of RNA sequencing data revealed that tumors with either high FAA levels or chromosome 9p loss had significantly fewer tumor-associated cytotoxic immune cells. CONCLUSIONS: Nonsquamous NSCLCs with high aneuploidy and chromosome 9p loss have a distinct tumor immune microenvironment and less favorable outcomes to ICIs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Alessi JV, Wang X, Elkrief A, et al. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023. PMID: 37247843. doi:10.1016/j.jtho.2023.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。